Key facts
- It has raised $11.5M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Wuxi Capital, V-Capital, Wuxi High-tech Zone Venture Capital Holding Group, Digital China Capital, Focus Fund (Beijing) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Newish (Beijing)
- ·The full record, as it builds
Funding rounds
No funding rounds for Newish (Beijing) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Newish (Beijing)
Developer of nucleic acid-based cancer therapeutics focused on early-stage treatment through first-in-class drugs with independent intellectual property. The company's STARi platform enables the development of targeted immunotherapy drugs, addressing unmet clinical needs and advancing innovative cancer treatments with the goal of global leadership in oncology drug development.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2014
- Employees
- 35
- Website
- newishes.com/
- Ownership
- Privately Held (backing)
Newish (Beijing) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Newish (Beijing) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Newish (Beijing) in its N-PORT filings yet. We sweep new filings monthly.